Lessons from Elsewhere — What Other TAs Are Doing BetterEpisode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch. We break down biomarker-tiered approaches and predictive outcome modeling from oncology; responder-based, modular reimbursement and pharmacy-channel starter kits from migraine; and concierge-style support with seamless financial triage from rare diseases. Then we map what’s portable, what’s risky, and where to pilot first.What you’ll learnWhich cross-TA tactics actually move access: biomarker-stratified messaging, responder-trial periods, and shared-outcomes payer pilots.How “pick-your-path” patient support UX, eRx onboarding, and pre-cert dashboards reduce friction and build trust.Where these models break at scale—and how to avoid payer pushback on perceived cost layering.Practical options for Lumara: concierge-lite tiering, precision framing for aligned phenotypes, and measured pilots with clear success criteria.Featured segmentsOncology to Asthma: Biomarker Playbooks that TranslateMigraine’s Modular Coverage: Trial, Respond, Then CommitRare Disease Services: Trust-Building at Scale—Without OverreachBottom line Cross-TA borrowing isn’t copy-paste. It’s selective translation—pilot what fits, prove value fast, and retire what doesn’t. 

Ver todos los episodios